非奈利酮在2型糖尿病合并慢性肾病治疗中的研究进展

doi:10.12092/j.issn.1009-2501.2022.09.015

中国临床药理学与治疗学 ›› 2022, Vol. 27 ›› Issue (9): 1067-1074.doi: 10.12092/j.issn.1009-2501.2022.09.015

非奈利酮在2型糖尿病合并慢性肾病治疗中的研究进展

翟葳葳1,2，余巧玲1,2，刘平1,2，邱博2，吴惠珍1,2

1河北医科大学研究生学院，石家庄 050017，河北；2河北省人民医院药学部，石家庄 050051，河北

收稿日期:2022-04-21 修回日期:2022-06-21 出版日期:2022-09-27 发布日期:2022-10-14
通讯作者: 吴惠珍，女，主任药师，硕士生导师，研究方向：临床药学。 E-mail: 13582005982@163.com
作者简介:翟葳葳，女，硕士，研究方向：临床药学。 E-mail: z13313249981@163.com
基金资助:
河北省自然科学基金青年基金项目（H2020307020）

Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease

ZHAI Weiwei1,2, YU Qiaoling1,2, LIU Ping1,2, QIU Bo2, WU Huizhen1,2

Graduate School of Hebei Medical University, Shijiazhuang 050017, Hebei, China

Received:2022-04-21 Revised:2022-06-21 Online:2022-09-27 Published:2022-10-14

摘要/Abstract

摘要： 非奈利酮是一种新型非甾体类盐皮质激素受体拮抗剂，通过抗氧化、抗炎、抗纤维化等作用对2型糖尿病合并慢性肾病起防治作用，并且具有显著的心血管保护作用。与传统盐皮质激素受体拮抗剂相比具有更高的选择性。本文对非奈利酮的基本介绍、基础研究、临床研究、局限性等进行了综述，目的是为2型糖尿病合并慢性肾病的治疗提供更多思路和选择。

关键词: 非奈利酮, 2型糖尿病合并慢性肾病, 盐皮质激素受体拮抗剂

Abstract: Finerenone is a new non-steroidal mineralocorticoid receptor antagonists, which can prevent and treat type 2 diabetes mellitus complicated with chronic kidney disease through antioxidant, anti-inflammatory and anti-fibrosis effects, and has a significant cardiovascular protection effect. Compared with traditional mineralocorticoid receptor antagonists, finerenone has a higher selectivity. In this review, the basic introduction, basic research, clinical research and limitations of finerenone were reviewed in order to provide more ideas and options for the treatment of type 2 diabetes mellitus complicated with chronic kidney disease.

Key words: finerenone, type 2 diabetes mellitus with chronic kidney disease, mineralocorticoid receptor antagonists

中图分类号:

R587

翟葳葳, 余巧玲, 刘平, 邱博, 吴惠珍. 非奈利酮在2型糖尿病合并慢性肾病治疗中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1067-1074.

ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.

[1]	彭娟, 范琳琳, 李然宜, 李晓宇, 吕迁洲, 邹云增. 心力衰竭药物治疗的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 373-381.
[2]	程宽. 非奈利酮的研究应用新进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 450-456.

非奈利酮在2型糖尿病合并慢性肾病治疗中的研究进展

Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

本文评价